MARKET

CLCS

CLCS

Cell Source Inc
OTCPK
0.400
-0.099
-19.87%
Closed 14:43 09/25 EDT
OPEN
0.477
PREV CLOSE
0.499
HIGH
0.477
LOW
0.400
VOLUME
3.02K
TURNOVER
1.21K
52 WEEK HIGH
2.250
52 WEEK LOW
0.310
MARKET CAP
27.18M
P/E (TTM)
-2.8011
1D
5D
1M
3M
1Y
5Y
1D
Cell Source presents program plans for haploidentical stem cell transplants
TipRanks · 05/21 13:27
About CLCS
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

Webull offers Cell Source Inc stock information, including OTCPK: CLCS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLCS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLCS stock methods without spending real money on the virtual paper trading platform.